PharmaTimes Media Ltd

PharmaTimes Media Ltd | July 05, 2017

In big news for Northern Ireland-headquartered drug discovery group Almac, US regulators have awarded orphan drug status to the firm’s experimental therapy for ovarian cancer. ALM201 is a first-in-class therapeutic peptide developed to mimic some of the properties of the naturally occurring protein FKBPL, known to have an effect on a number of important tumour biology processes, including cancer stem cells and angiogenesis....

PharmaTimes Media Ltd | June 05, 2017

An experimental targeted treatment for ovarian cancer has shown promise in early clinical trials shrinking tumours in half of women with the disease. Researchers from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust tested the drug - known in the study as ONX-0801 - in 15 women with ovarian cancer as part of a wider Phase I clinical trial....

PharmaTimes Media Ltd | November 13, 2017

The European Medicines Agency’s Committee for Medicinal Products for Human Use has put 10 medicines forward for approval in the region, including new options for multiple sclerosis, eosinophilic esophagitis, and eosinophilic asthma....

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...